dpp-4 inhibitors and glp-1 agonists Glucagon-like peptide-1 Were DPP-4 inhibitors the original
Description
however, to our knowledge, no larger clinical trials with GLP-1 RAs in HFrEF are ongoing
That review also suggests that the weight loss effects may be short-lived due to the way these drugs work
In a randomized, placebo-controlled Phase 2a trial, PP405 met its primary safety endpoint and secondary pharmacokinetic endpoint, showed no systemic absorption, and was well tolerated across a diverse patient population
Follow-up appointments are required to receive refills
The primary endpoint was the percentage change in body weight from baseline to 24 weeks
